hVIVO plc
Research hVIVO plc (HVO) on Bullrun: market cap GBX 4.51B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHVO
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyGBX
- Market capGBX 4.51B
- Financial periodFY2025
- RevenueGBP 46.77M
- Revenue growth-25.4%
- Net income-GBP 5.99M
- Free cash flow-GBP 15.85M
Valuation Snapshot
latest market cap is GBX 4.51B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 46.77M | -GBP 5.99M | -GBP 15.85M | n/a | -0.01 | GBP 14.30M | GBP 14.79M | GBP 38.16M |
| FY2024 | GBP 62.73M | GBP 10.65M | GBP 7.88M | n/a | 0.02 | GBP 44.18M | GBP 12.90M | GBP 44.68M |
| FY2023 | GBP 56.04M | GBP 16.12M | GBP 12.06M | n/a | 0.02 | GBP 36.97M | GBP 12.53M | GBP 34.33M |
| FY2022 | GBP 48.48M | -GBP 776.00K | GBP 14.62M | n/a | 0 | GBP 28.44M | GBP 1.56M | GBP 20.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | GBX 4.51B | n/a | 2.7% | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.2 GBP |
| FY2024 | 0.2 GBP |
| FY2023 | 0.45 GBP |
About hVIVO plc
hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is hVIVO plc's market cap?
hVIVO plc's market capitalization is GBX 4.51B.
What does hVIVO plc do?
hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation.